Nature Communications (Oct 2021)
Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics
- María Gordillo-Marañón,
- Magdalena Zwierzyna,
- Pimphen Charoen,
- Fotios Drenos,
- Sandesh Chopade,
- Tina Shah,
- Jorgen Engmann,
- Nishi Chaturvedi,
- Olia Papacosta,
- Goya Wannamethee,
- Andrew Wong,
- Reecha Sofat,
- Mika Kivimaki,
- Jackie F. Price,
- Alun D. Hughes,
- Tom R. Gaunt,
- Deborah A. Lawlor,
- Anna Gaulton,
- Aroon D. Hingorani,
- Amand F. Schmidt,
- Chris Finan
Affiliations
- María Gordillo-Marañón
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Magdalena Zwierzyna
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Pimphen Charoen
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Fotios Drenos
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Sandesh Chopade
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Tina Shah
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Jorgen Engmann
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Nishi Chaturvedi
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Olia Papacosta
- Primary Care and Population Health, University College London
- Goya Wannamethee
- Primary Care and Population Health, University College London
- Andrew Wong
- MRC Unit for Lifelong Health and Ageing, University College London
- Reecha Sofat
- Institute of Health Informatics, University College London
- Mika Kivimaki
- Department of Epidemiology and Public Health, University College London
- Jackie F. Price
- Usher Institute, University of Edinburgh
- Alun D. Hughes
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Tom R. Gaunt
- MRC Integrative Epidemiology Unit at the University of Bristol
- Deborah A. Lawlor
- MRC Integrative Epidemiology Unit at the University of Bristol
- Anna Gaulton
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton
- Aroon D. Hingorani
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Amand F. Schmidt
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Chris Finan
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- DOI
- https://doi.org/10.1038/s41467-021-25731-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Drug target Mendelian randomization (MR) uses genetic variation in or near a gene encoding a drug target to anticipate the effect of drug action on the same target. Using drug target MR, the authors prioritized 30 targets that might elicit beneficial effects in the prevention or treatment of coronary heart disease.
